A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Biology October 28, 2023 DOI: 10.3390/biology12111380 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Mental illness Mental health |
| Citations | 26 |
| Key findings | Psychedelics may exert therapeutic effects through 5-HT2A receptor signaling and promotion of plasticity via the TrkB-BDNF pathway, and they show potential as anti-inflammatory agents. |
Abstract
Psychedelic substances have gained significant attention in recent years for their potential therapeutic effects on various psychiatric disorders. This review delves into the intricate cellular neurobiology of psychedelics, emphasizing their potential therapeutic applications in addressing the global burden of mental illness. It focuses on contemporary research into the pharmacological and molecular mechanisms underlying these substances, particularly the role of 5-HT2A receptor signaling and the promotion of plasticity through the TrkB-BDNF pathway. The review also discusses how psychedelics affect various receptors and pathways and explores their potential as anti-inflammatory agents. Overall, this research represents a significant development in biomedical sciences with the potential to transform mental health treatments.
Citations in the library
Cited by 22
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025
- Do the therapeutic effects of psilocybin involve actions in the gut? TIPS - Trends in Pharmacological Sciences February 1, 2024
- Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options. Journal of Clinical Medicine March 17, 2024
- Epigenetic Echoes: Bridging Nature, Nurture, and Healing Across Generations. International Journal of Molecular Sciences March 27, 2025
- Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats Frontiers in Neuroscience May 1, 2025
and 17 more in the library
Cites 181
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate British Journal of Pharmacology June 1, 1983
and 176 more in the library